Results 261 to 270 of about 1,543,966 (410)

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

The Lancet, 2017
D. Athauda, K. Maclagan, Simon S. Skene, Martha Bajwa-Joseph, D. Letchford, Kashfia Chowdhury, S. Hibbert, N. Budnik, L. Zampedri, J. Dickson, Yazhou Li, I. Avilés-Olmos, T. Warner, P. Limousin, A. Lees, N. Greig, S. Tebbs, T. Foltynie   +17 more
semanticscholar   +1 more source

Ivarmacitinib reduces the need for adding/escalating medications in moderate-to-severe rheumatoid arthritis patients: a <i>post hoc</i> analysis from a phase III trial. [PDF]

Front Pharmacol
Liu H, Li J, Song L.
europepmc   +1 more source

Re: Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double‐blind, randomised, placebo‐controlled, multi‐centre trial

, 2020
Mads Langager Larsen, Lone Krebs, Gija Rackauskaite, Christina Engel Hoei‐Hansen, Gorm Greisen   +4 more
openalex   +2 more sources

Global Recruiting Patterns and Placebo Response Rates in Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis

Arthritis &Rheumatology, EarlyView.
Objective Placebo effects are a significant challenge in the conduct of clinical trials. We explored how global recruitment patterns influence the extent of placebo responses in randomized controlled trials of psoriatic arthritis and plaque psoriasis.
Andreas Kerschbaumer, Marlene Steiner, Suzanne Khalili, Azad Shehab, Alexander Jordanov, Brigitte Wildner, Magdalena Maad, Josef S. Smolen, Daniel Aletaha   +8 more
wiley   +1 more source

Effectiveness of gabapentinoids in orthopedic surgeries: a systematic review and meta-analysis of postoperative pain, and opioid-sparing effects. [PDF]

BMC Anesthesiol
Almuqad FA, Almuhammady AA, Alsaedi GT, Osailan JA, Alalawi SI, Rahmah Allah YA, Osailan A.   +6 more
europepmc   +1 more source

Placebo CRT [PDF]

Journal of Cardiovascular Electrophysiology, 2008
Niraj, Varma, Ping, Jia, Yoram, Rudy
openaire   +2 more sources

S7A:4 Reduction of systemic lupus flares by atacicept in a randomised, placebo-controlled, phase iib study (address ii) and its extension study [PDF]

, 2018
DJ Wallace, David Isenberg, Amy Kao, Cristina Vazquez‐Mateo, Patricia Fleuranceau-Morel, Peter Chang, JT Merril   +6 more
openalex   +1 more source

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

New England Journal of Medicine, 2012
S. Verstovsek, R. Mesa, J. Gotlib, R. Levy, Vikas Gupta, J. Dipersio, J. Catalano, M. Deininger, Carole B. Miller, R. Silver, M. Talpaz, E. Winton, J. Harvey, M. Arcasoy, E. Hexner, R. Lyons, R. Paquette, A. Raza, K. Vaddi, S. Erickson‐Viitanen, I. Koumenis, William Sun, V. Sandor, H. Kantarjian   +23 more
semanticscholar   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

Arthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman, Voon Ong, Christopher P. Denton   +2 more
wiley   +1 more source

Probiotic Supplementation Can Alter Inflammation Parameters and Self-Reported Sleep After a Marathon: A Randomized, Double-Blind, Placebo-Controlled Study. [PDF]

Nutrients
Aquino-Lemos V, Leite GSF, T Silva E, Batatinha HAP, Resende AS, Lancha-Junior AH, R Neto JC, Tufik S, Thomatieli-Santos RV.   +8 more
europepmc   +1 more source